Some Winners Emerge Despite China’s Reimbursement Price-Cutting Scheme
Higher Volumes Benefit Selected PD-1s
Executive Summary
Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.